A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity

Status:
Not yet recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

The purpose of the study was to assess the efficacy of LB54640 in participants with rare genetic disorders of obesity

Phase 2

LG Chem